The American Journal of Digestive Diseases

, Volume 16, Issue 1, pp 61–80 | Cite as

Alterations in immunologic mechanisms in diseases of the gastrointestinal tract

  • Allen L. Ginsberg
Progress Reports

Conclusion

No disease of the gastrointestinal tract has clearly been shown to be of immune or autoimmune etiology, although many alterations in immunologic mechanisms have been observed. This progress report has attempted to review many of these alterations and to organize them, at times by use of speculation, into meaningful patterns. Future investigation will provide data on which to base a more informed appraisal of the role of immunologic mechanisms in diseases of the gut.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    South MA, Cooper MD, Wollheim FA, et al: The IgA System. Amer J Med 44:168, 1968CrossRefPubMedGoogle Scholar
  2. 2.
    Tomasi TB: Human Immunoglobulin A. New Eng J Med 279:1327, 1968PubMedGoogle Scholar
  3. 3.
    Ogra PL, Karzon DT, Righthand F, et al: Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. New Eng J Med 279:893, 1968Google Scholar
  4. 4.
    Waldman RH, Mann JJ, Small PA Jr: Immunization against influenza: prevention of illness in man by aerosolized inactivated vaccine. JAMA 207:520, 1969CrossRefPubMedGoogle Scholar
  5. 5.
    Bellanti JA, Sanga RL, Klutinis B, et al: Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccine. New Eng J Med 280:628, 1969PubMedGoogle Scholar
  6. 6.
    Scott TFM, Bonanno DE: Reactions to live-measles virus in children previously inoculated with killed-virus vaccine. New Eng J Med 277:248, 1967PubMedGoogle Scholar
  7. 7.
    Buser F: Side reaction to measles vaccination suggesting Arthus phenomenon. New Eng J Med 277:250, 1967PubMedGoogle Scholar
  8. 8.
    Tomasi TB: The gamma A globulins: first line of defense. Hosp Pract 1:26, 1967Google Scholar
  9. 9.
    Brandtzaeg P, Fjellanger I, Gjeruldsen ST: Adsorption of immunoglobulin A onto oral bacteria in vivo. J Bact 96:242, 1968PubMedGoogle Scholar
  10. 10.
    Burrows W, Elliot ME, Havens I: Studies on immunity to Asiatic cholera. J Infect Dis 81:261, 1947Google Scholar
  11. 11.
    Freter R: Comparison of immune mechanisms in various experimental models of cholera. Bull WHO 31:825, 1964PubMedGoogle Scholar
  12. 12.
    Hermans PE, Huizenga KA, Hoffman HN, et al: Dysgammaglobulinemia associated with nodular lymphoid hyperplasia of the small intestine. Amer J Med 40:78. 1966CrossRefPubMedGoogle Scholar
  13. 13.
    Twomey JJ, Jordan PH, Jarrold T, et al: The syndrome of immunoglobulin deficiency and pernicious anemia. Amer J Med 47:340, 1969CrossRefPubMedGoogle Scholar
  14. 14.
    Chilgren RA, Meuwissen NJ, Quie PG, et al: Chronic mucocutaneous candidiasis, deficiency of delayed hypersensitivity, and selective local antibody defect. Lancet 2:688, 1967CrossRefPubMedGoogle Scholar
  15. 15.
    Rivera E, Maldonado N, Velez-Garcia E, et al: Hyperinfection syndrome with strongyloides stercoralis. Ann Intern Med 72:199, 1970PubMedGoogle Scholar
  16. 16.
    Bicks RO, Azar MM, Rosenberg EW, et al: Delayed hypersensitivity reactions in the intestinal tract. Gastroenterology 53:422, 1967Google Scholar
  17. 17.
    Jeffries GH, Sleisenger MN: Studies of parietal cell antibody in pernicious anemia. J Clin Invest 44:2021, 1965PubMedGoogle Scholar
  18. 18.
    Samloff IM, Kleinman MS, Turner MD, et al: Blocking and binding antibodies to intrinsic factor and parietal cell antibody in pernicious anemia. Gastroenterology 55:575, 1968PubMedGoogle Scholar
  19. 19.
    Broberger O, Perlmann P: Autoantibodies in human ulcerative colitis. J Exp Med 110:657, 1959CrossRefPubMedGoogle Scholar
  20. 20.
    Doniach D, Roitt IM, Walker JG, et al: Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis, and other liver diseases and their clinical implications. Clin Exp Immun 1:237, 1966PubMedGoogle Scholar
  21. 21.
    Irvine JW: Immunologic aspects of pernicious anemia. New Eng J Med 273:432, 1965PubMedGoogle Scholar
  22. 22.
    Fisher JM, Taylor KB: A comparison of autoimmune phenomena in pernicious anemia and chronic atrophic gastritis. New Eng J Med 272:499, 1965PubMedGoogle Scholar
  23. 23.
    Ardeman S, Chanarin I, Krafchik B, et al: Addisonian pernicious anemia and intrinsic factor antibodies in thyroid disorders. Quart J Med 35:421, 1966PubMedGoogle Scholar
  24. 24.
    Jeffries GH, Todd JE, Sleisenger MH: The effect of prednisone on gastric mucosal histology, gastric secretion, and vitamin B12 absorption in patients with pernicious anemia. J Clin Invest 45:803, 1966PubMedGoogle Scholar
  25. 25.
    Ardeman S, Chanarin I: Steroids and Addisonian pernicious anemia. New Eng J Med 273:1352, 1965PubMedGoogle Scholar
  26. 26.
    Conn HO, Binder H, Burns B: Pernicious anemia and immunoglobulin deficiency. Ann Intern Med 68:603, 1968PubMedGoogle Scholar
  27. 27.
    Ginsberg AL, Mullinax F: Pernicious anemia and monoclonal gammopathy in a patient with IgA deficiency. Amer J Med 48:787, 1970PubMedGoogle Scholar
  28. 28.
    Odgers RJ, Wangel AG: Abnormalities in IgA containing mononuclear cells in the gastric lesion of pernicious anemia. Lancet 2:846, 1968CrossRefPubMedGoogle Scholar
  29. 29.
    Carmel R, Herbert V: Presence of “precipitating” or “blocking” antibody to intrinsic factor in gastric juice or serum of nearly all pernicious anemia patients. Clin Res 14:282, 1966Google Scholar
  30. 30.
    Schade SG, Feick P, Muckerheide M, et al: Occurrence in gastric juice of antibody to a complex of intrinsic factor and vitamin B12. New Eng J Med 275:528, 1966PubMedGoogle Scholar
  31. 31.
    Carmel R, Herbert V: Intrinsic factor antibody in the saliva of a patient with pernicious anemia. Lancet 1:80, 1967CrossRefPubMedGoogle Scholar
  32. 32.
    Goldberg LS, Shuster J, Stuckey M, et al: Secretory immunoglobulin A: autoantibody activity in gastric juice. Science 160:1240, 1968PubMedGoogle Scholar
  33. 33.
    Ardeman S, Chanarin I: A method for the assay of human gastric intrinsic factor and for the detection and titration of antibodies against intrinsic factor. Lancet 2:1350, 1963CrossRefGoogle Scholar
  34. 34.
    Gottlieb C, Lau KS, Wasserman LR, et al: Rapid charcoal assay for intrinsic factor, gastric juice unsaturated B12 binding capacity, antibody to intrinsic factor, and serum unsaturated B12 binding capacity. Blood 25:875, 1965PubMedGoogle Scholar
  35. 35.
    Goldberg LS, Bluestone R: Hidden gastric autoantibodies to intrinsic factor in pernicious anemia. J Lab Clin Med 75:449, 1970PubMedGoogle Scholar
  36. 36.
    Rose MS, Chanarin I: Dissociation of intrinsic factor from its antibody: application to study of pernicious anemia gastric juice specimens. Brit Med J 1:468, 1969PubMedGoogle Scholar
  37. 37.
    Jeffries GH, Hoskins DW, Sleisenger MH: Antibody to intrinsic factor in serum from patients with pernicious anemia. J Clin Invest 41:1106, 1962PubMedGoogle Scholar
  38. 38.
    Ardeman S, Chanarin I: Intrinsic factor antibodies and intrinsic factor mediated vitamin B12 absorption in pernicious anemia. Gut 6:436, 1965PubMedGoogle Scholar
  39. 39.
    Smith WO, DuVal MK, Joel W, et al: Gastric atrophy in dogs induced by administration of normal human gastric juice. Gastroenterology 39:55, 1960PubMedGoogle Scholar
  40. 40.
    Fixa BO, Vejbora O, Komarkova O, et al: On immunologically induced gastric atrophy in dogs. Gastroenterologia 102:331, 1964PubMedGoogle Scholar
  41. 41.
    Walder AJ: Histologic and secretory changes after induced immunity to parietal cells. Surg Forum 17:302, 1966PubMedGoogle Scholar
  42. 42.
    Hausamen TU, Halcrow DA, Taylor KB: Biological effects of gastrointestinal antibodies: the production of antibodies to components of adult and fetal guinea pig gastric and colonic mucosa. Gastroenterology 56:1053, 1969PubMedGoogle Scholar
  43. 43.
    Hausamen TU, Halcrow DA, Taylor KB: Biological effects of gastrointestinal antibodies: histological changes in the stomach induced by injection of specific heterologous antibodies.Gastroenterology 56:1062, 1969PubMedGoogle Scholar
  44. 44.
    Tanaka N, Glass GBJ: Effect of prolonged administration of parietal cell antibodies from patients with atrophic gastritis and pernicious anemia on the parietal cell mass and hydrochloric acid output in rats. Gastroenterology 58:482, 1970PubMedGoogle Scholar
  45. 45.
    Rice-Oxley JM, Truelove S: Complications of ulcerative colitis. Lancet 1:607, 1950CrossRefGoogle Scholar
  46. 46.
    Lagercrantz R, Winberg J, Zetterström R: Extra-colonic manifestations in chronic ulcerative colitis. Acta Paediat 47:675, 1958Google Scholar
  47. 47.
    Bowen GE, Irons GV Jr, Rhodes JB, et al: Early experiences with azathioprine in ulcerative colitis. JAMA 195:460, 1966CrossRefPubMedGoogle Scholar
  48. 48.
    Deodhar SD, Michener WM, Farmer RG: A study of the immunologic aspects of chronic ulcerative colitis and transmural colitis. Amer J Clin Path 51:591, 1969Google Scholar
  49. 49.
    Elshlepp JG, Kirsner JB: Studies on experimental ulcerative colitis. Proc Centr Soc Clin Res 28:27, 1955Google Scholar
  50. 50.
    Kirsner JB, Elshlepp JG: The production of an experimental ulcerative colitis in rabbits. Trans Ass Amer Physicians 19:102, 1957Google Scholar
  51. 51.
    Goldgraber MB, Kirsner JB: Arthus phenomenon in the colon of rabbits. Arch Path 67:582, 1959Google Scholar
  52. 52.
    Asheron GL, Broberger O: Incidence of hemagglutinating and complement-fixing antibodies. Brit Med J 1:1429, 1961Google Scholar
  53. 53.
    Thayer WR Jr, Brown M, Sangree MH, et al: Escherichia coli 0:14 and colon hemagglutinating antibodies in inflammatory bowel disease. Gastroenterology 57:311, 1969PubMedGoogle Scholar
  54. 54.
    Lagercrantz R, Hammarström S, Perlmann P, et al: Immunological studies in ulcerative colitis. Clin Exp Immun 1:263, 1966PubMedGoogle Scholar
  55. 55.
    Watson DW, Quigley A, Bolt RJ: Effect of lymphocytes from patients with ulcerative colitis on human adult colon epithelial cells. Gastroenterology 51:985, 1966PubMedGoogle Scholar
  56. 56.
    Shorter RG, Spencer RJ, Huizenga KA, et al: Inhibition of in vitro cytotoxicity of lymphocytes from patients with ulcerative colitis and granulomatous colitis for allogenic colonic epithelial cells using horse anti-thymus serum. Gastroenterology 54:227, 1968PubMedGoogle Scholar
  57. 57.
    Shorter RG, Cardoza M, Spencer RJ, et al: Further studies of in vitro cytotoxicity of lymphocytes from patients with ulcerative and granulomatous colitis for allogenic colonic epithelial cells. including the effects of colectomy. Gastroenterology 56:304, 1969PubMedGoogle Scholar
  58. 58.
    Perlmann P, Hammarström S, Lagercrantz R, et al: Autoantibodies to colon in rats and human ulcerative colitis: cross reactivity with Escherichia coli 0:14 antigen. Proc Soc Exp Biol Med 125:975, 1967PubMedGoogle Scholar
  59. 59.
    Kaplan MH: Autoimmunity to heart, Textbook of Immunopathology (Vol 2, Chap 51). Edited by PA Miescher, HJ Müller-Eberhard. New York and London, Grune & Stratton, Inc, 1969Google Scholar
  60. 60.
    Asheron GL, Holborow EJ: Autoantibody production in rabbits. Immunology 10:161, 1966PubMedGoogle Scholar
  61. 61.
    Watson DW: Immune responses and the gut. Gastroenterology 56:944, 1969PubMedGoogle Scholar
  62. 62.
    Taylor KB, Truelove SC: Circulatory antibodies to milk proteins in ulcerative colitis. Brit Med J 2:924, 1961Google Scholar
  63. 63.
    Shorter RG, Cardoza M, Huizenga KA, et al: Further studies of in vitro cytotoxicity of lymphocytes for colon epithelial cells: induction of cytotoxicity in normal lymphocytes. Gastroenterology 56:1197, 1969Google Scholar
  64. 64.
    Shorter RG, Cardoza MR, Remine SG, et al: Modification of in vitro cytotoxicity of lymphocytes from patients with chronic ulcerative colitis or granulomatous colitis for allogenic colonic epithelial cells. Gastroenterology 58:692, 1970PubMedGoogle Scholar
  65. 65.
    Kolb WP, Granger GA: Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. Proc Nat Acad Sci 61:1250, 1968PubMedGoogle Scholar
  66. 66.
    Taylor KB, Truelove SC: Immunological reactions in gastrointestinal disease: a review. Gut 3:277, 1962PubMedGoogle Scholar
  67. 67.
    Brooke BN, Hoffman DC, Swarbrick ET: Azathioprine for Crohn's disease. Lancet 2:612, 1969CrossRefPubMedGoogle Scholar
  68. 68.
    Jones VJ, Housley J, Ashurst PM, et al: Development of delayed hypersensitivity to dinitrochlorobenzene in patients with Crohn's disease. Gut 10:52, 1969PubMedGoogle Scholar
  69. 69.
    Soltoft J: Immunoglobulin containing cells in normal jejunal mucosa and in ulcerative colitis and regional enteritis. Scand J Gastroent 4:353, 1969PubMedGoogle Scholar
  70. 70.
    Eggert RC, Wilson ID, Good RA: Agammagobulinemia and regional enteritis. Ann Intern Med 71:581, 1969PubMedGoogle Scholar
  71. 71.
    Slaney G: Hypersensitivity and the alimentary tract. Ann Roy Coll Surg Eng 31:249, 1962PubMedGoogle Scholar
  72. 72.
    Bendixen G: Cellular hypersensitivity to components of intestinal mucosa in ulcerative colitis and Crohn's disease. Gut 10:631, 1969PubMedGoogle Scholar
  73. 73.
    Kivel RM, Kearns DH, Liebowitz D: Significance of antibodies to dietary proteins in the serums of patients with nontropical sprue. New Eng J Med 271:769, 1964PubMedGoogle Scholar
  74. 74.
    Alarcon-Segovia D, Herskovic T, Wakim KG, et al: Presence of circulating antibodies to gluten and milk fractions in patients with non-tropical sprue. Amer J Med 36:485, 1964CrossRefPubMedGoogle Scholar
  75. 75.
    Katz J, Kantor FS, Herskovic T: Intestinal antibodies to wheat fractions in celiac disease. Ann Intern Med 69:1149, 1968PubMedGoogle Scholar
  76. 76.
    Herskovic T, Katz J, Gryboski JD, et al: Coproantibodies to gluten in celiac disease. JAMA 203:887, 1968CrossRefPubMedGoogle Scholar
  77. 77.
    Belcher TE, Ajdukiewicz AB, McCarthy CF, et al: Serum immunoglobulins and lymphocyte transformation studies in coeliac disease. Gut 10:57, 1969PubMedGoogle Scholar
  78. 78.
    Asquith P, Thompson RA, Cooke WT: Serum immunoglobulins in adult coeliac disease. Lancet 2:129, 1969CrossRefPubMedGoogle Scholar
  79. 79.
    Brown DL, Cooper AG, Hepner GW: IgM metabolism in coeliac disease. Lancet 1:858, 1969CrossRefPubMedGoogle Scholar
  80. 80.
    Hobbs JR, Hepner GW, Douglas AP, et al: Immunological mystery of coeliac disease. Lancet 2:649, 1969CrossRefPubMedGoogle Scholar
  81. 81.
    Huizenga KA, Wollaeger EE, Green PA, et al: Serum globulin deficiencies in non-tropical sprue, with report of two cases of acquired agammaglobulinemia. Amer J Med 31:572, 1961CrossRefPubMedGoogle Scholar
  82. 82.
    Harris OD, Cooke WT, Thompson H. et al: Malignancy in adult coeliac disease and idiopathic steatorrhea. Amer J Med 42:899, 1967CrossRefPubMedGoogle Scholar
  83. 83.
    Wall AJ, Douglas AP, Booth CC, et al: Response of the jejunal mucosa in adult coeliac disease to oral prednisolone. Gut 11:7, 1970PubMedGoogle Scholar
  84. 84.
    LePore MJ: Long-term or maintenance adrenal steroid therapy in nontropical sprue. Amer J Med 25:381, 1958CrossRefPubMedGoogle Scholar
  85. 85.
    Rubin CE, Fauci AS, Sleisenger MH, et al: Immunofluorescent studies in celiac disease. J Clin Invest 44:455, 1965Google Scholar
  86. 86.
    Cohen N, Paley D, Janowitz HD: Acquired hypogammaglobulinemia and sprue: report of a case and review of the literature. J Mt Sinai Hosp 28:421, 1961Google Scholar
  87. 87.
    Finklestein MS, Uhr JW: Specific inhibition of antibody formation by passively administered 19S and 7S antibody. Science 146:67, 1964PubMedGoogle Scholar
  88. 88.
    Crabbé PA, Heremans JF: Selective IgA deficiency with steatorrhea. Amer J Med 42:319, 1967CrossRefPubMedGoogle Scholar
  89. 89.
    Page AR, Hansen AE, Good RA: Occurrence of leukemia and lymphoma in patients with agammaglobulinemia. Blood 21:197, 1963PubMedGoogle Scholar
  90. 90.
    Burnet FM: Immunological aspects of malignant disease. Lancet 1:1171, 1967CrossRefPubMedGoogle Scholar
  91. 91.
    Alperstein BB: Oral vs parenteral pollen therapy: clinical study. J Allerg 11:498, 1940CrossRefGoogle Scholar
  92. 92.
    Iliff E, Gay L: Oral treatment of hay fever with ragweed pollen. Bull Hopkins Hosp 70:378, 1942Google Scholar
  93. 93.
    Gairdner D: Schoenlein-Henoch syndrome (anaphylactoid purpura). Quart J Med 17:95, 1948Google Scholar
  94. 94.
    Clemett AR, Fishbone G, Levine RJ, et al: Gastrointestinal lesions in mastocytosis. Amer J Roentgen 103:405, 1968PubMedGoogle Scholar
  95. 95.
    Pollard HM, Stuart GJ: Experimental reproduction of gastric allergy in human beings with controlled observations on the mucosa. J Allerg 13:467, 1941CrossRefGoogle Scholar
  96. 96.
    Davidson M, Burnstine RC, Kugler MM, et al: Malabsorption defect induced by ingestion of beta lactoglobulin. J Pediat 66:545, 1965PubMedGoogle Scholar
  97. 97.
    Ingelfinger FJ, Lowell FC, Franklin W: Gastrointestinal allergy. New Eng J Med 241:303, 1949Google Scholar
  98. 98.
    Waldman TA, Wochner RD, Laster L, et al: Allergic gastroenteropathy: a cause of excessive gastrointestinal protein loss. New Eng J Med 276:761, 1967Google Scholar
  99. 99.
    Greenberger NJ, Tennenbaum JI, Ruppert RD: Protein-losing enteropathy associated with gastrointestinal allergy. Amer J Med 43:777, 1967CrossRefPubMedGoogle Scholar
  100. 100.
    Scudamore HH, Phillips SF, Swedlund HA, et al: Allergic gastroenteropathy manifested by malabsorption syndrome, lactase deficiency, decreased immunoglobulins and excessive protein loss. Gastroenterology 56:1197, 1969Google Scholar
  101. 101.
    Katz J, Spiro HM, Herskovic T: Milk-precipitating substance in the stool in gastrointestinal milk sensitivity. New Eng J Med 278:1191, 1968PubMedGoogle Scholar
  102. 102.
    Davis SD, Bierman CW, Pierson WE, et al: Clinical nonspecificity of milk copro-antibodies in diarrheal stools. New Eng J Med 282:612, 1970PubMedGoogle Scholar
  103. 103.
    Buckley RH, Dees SC: Correlation of milk precipitins with IgA deficiency. New Eng J Med 281:465, 1969PubMedGoogle Scholar
  104. 104.
    Herskovic T, Alarcon-Segovia D, Bartholomew LG, et al: Immune mechanisms in chronic pancreatic disease II. Amer J Dig Dis 11:40, 1966PubMedGoogle Scholar
  105. 105.
    Murray MJ, Thal AP: The clinical significance of circulating pancreatic antibodies. Ann Intern Med 53:548, 1960PubMedGoogle Scholar
  106. 106.
    Fonkalsrud EW, Longmire WP Jr: The occurrence of pancreatic antibodies and the experimental production of pancreatitis with pancreatic antiserum. Surgery 50:134, 1961PubMedGoogle Scholar
  107. 107.
    Debray C, Lods JC: Les anticorps antipancreas dans le serum: leur interet dans les pancreatites. Rev Int Hepat 13:215, 1963PubMedGoogle Scholar
  108. 108.
    Valenzuela J, Hoecker G, Ugarte G: Anticuerpos en enfermedades pancreaticos. Rev Med Chile 91:725, 1963PubMedGoogle Scholar
  109. 109.
    Alarcon-Segovia D, Herskovic T, Wakim KG, et al: Immune mechanisms in chronic pancreatic disease I. Amer J Dig Dis 9:845, 1964CrossRefGoogle Scholar
  110. 110.
    Yalow RS, Berson SA: Immunologic aspects of insulin. Amer J Med 31:882, 1961CrossRefPubMedGoogle Scholar
  111. 111.
    Kalkay MN, Bergen SS Jr: Insulin-resistent diabetes mellitus. Postgrad Med 47:107, 1970PubMedGoogle Scholar
  112. 112.
    Mackay IR: Lupoid hepatitis and primary biliary cirrhosis: autoimmune diseases of the liver? Bull Rheum Dis 18:487, 1968Google Scholar
  113. 113.
    Mackay IR: The problem of persisting destructive disease of the liver. Gastroenterology 40:617, 1961PubMedGoogle Scholar
  114. 114.
    Doniach D, Walker JG: A unified concept of autoimmune hepatitis. Lancet 1:813, 1969CrossRefPubMedGoogle Scholar
  115. 115.
    Paronetto F, Schaffner F, Popper H: Immunocytochemical and serologic observations in primary biliary cirrhosis. New Eng J Med 271:1123, 1964PubMedGoogle Scholar
  116. 116.
    Block MA, LoGrippo GA, Fox TA Jr: Primary biliary cirrhosis. Amer J Surg 117:69, 1969CrossRefPubMedGoogle Scholar
  117. 117.
    Doniach D, Roitt IM, Walker JG, et al: Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immun 1:237, 1966PubMedGoogle Scholar
  118. 118.
    Arter WJ, Perkins KW, Blackburn CRB: Experience with the use of 6-mercaptopurine and “Imuran” in the treatment of progressive hepatitis (active chronic hepatitis). Aust Ann Med 15:222, 1966Google Scholar
  119. 119.
    Geenen JE, Hensley GT, Winship DH: Chronic active hepatitis treated with 6-mercaptopurine sustained remission. Ann Intern Med 65:1277, 1966PubMedGoogle Scholar
  120. 120.
    Page AR, Condie RM, Good RA: The suppression of plasma cell hepatitis with 6-mercaptopurine. Amer J Med 36:200, 1964CrossRefPubMedGoogle Scholar
  121. 121.
    Paronetto F, Popper H: Hetero-iso- and autoimmune phenomena in the liver, Textbook of Immunopathology (Vol. 2, Chap 45). Edited by PA Meischer, HJ Müler-Eberhard. New York and London, Grune and Stratton, Inc, 1969Google Scholar
  122. 122.
    Paronetto F: Immunologic aspects of liver diseases, Progress in Liver Diseases (Vol 3, Chap 19). Edited by H Popper, F Schaffner. New York and London, Grune & Stratton, Inc, 1970Google Scholar
  123. 123.
    Almeida JD, Waterson AP: Immune complexes in hepatitis. Lancet 2:983, 1969CrossRefPubMedGoogle Scholar
  124. 124.
    Bayer ME, Blumberg BS, Werner B: Particles associated with Australia antigen in the sera of patients with leukemia, Down's syndrome, and hepatitis. Nature 218:1057, 1968PubMedGoogle Scholar
  125. 125.
    Millman I, Zevatone V, Gerstley BJS, et al: Australia antigen in the nuclei of liver cells of patients with viral hepatitis detected by the fluorescent antibody technique. Nature 222:181, 1969Google Scholar
  126. 126.
    Blumberg BS, Sutnick AI, London WT: Australia antigen as a hepatitis virus: variation in host response. Amer J Med 48:1, 1970CrossRefPubMedGoogle Scholar
  127. 127.
    Gocke DJ, Kavey NB: Hepatitis antigen. Lancet 1:1055, 1969CrossRefPubMedGoogle Scholar
  128. 128.
    Krugman S: Etiology of viral hepatitis. Hosp Pract 3:45, 1970Google Scholar
  129. 129.
    Krugman S, Giles JP: Viral hepatitis: new light on an old disease. JAMA 212:1019, 1970CrossRefPubMedGoogle Scholar
  130. 130.
    London WT, Difiglia M, Sutnick AI, et al: An epidemic of hepatitis in a chronic hemodialysis unit: Australia antigen and differences in host response. New Eng J Med 281:571, 1969PubMedGoogle Scholar
  131. 131.
    Oldstone MBA, Dixon FJ: Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection. I. Relationship of antibody production to disease in neonatally infected mice. J Exp Med 129:483, 1969CrossRefPubMedGoogle Scholar

Copyright information

© Hoeber Medical Division • Harper & Row, Publisers, Incorporated 1971

Authors and Affiliations

  • Allen L. Ginsberg
    • 1
  1. 1.From the Division of Gastroenterology, Department of Medicine, Medical College of Virginia School of MedicineVirginia Commonwealth UniversityRichmond
  2. 2.Department of MedicineWalter Reed Army Institute of ResearchWashington, DC

Personalised recommendations